<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02966756</url>
  </required_header>
  <id_info>
    <org_study_id>M14-728</org_study_id>
    <secondary_id>2017-002413-54</secondary_id>
    <nct_id>NCT02966756</nct_id>
  </id_info>
  <brief_title>A Study of Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia in the Presence of 17p Deletion</brief_title>
  <official_title>A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia in the Presence of 17p Deletion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, open-label, single-arm, multicenter study, evaluating the efficacy of
      venetoclax in participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) in
      the presence of 17p deletion.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2017</start_date>
  <completion_date type="Anticipated">April 29, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 29, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Measured up to 2 years after the last participant has enrolled in the study.</time_frame>
    <description>ORR is the proportion of participants with an overall response (complete remission [CR], plus complete remission with incomplete bone marrow recovery [CRi], plus nodular partial remission [nPR], plus partial remission [PR]) per the National Cancer Institute-Working Group (NCI-WG) guidelines as assessed by the Independent Review Committee (IRC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Partial Remission (PR) rate</measure>
    <time_frame>Measured up to 2 years after the last participant has enrolled into the study.</time_frame>
    <description>PR rate is defined as the proportion of subjects who achieved nPR or PR per the NCI-WG criteria (determined by the IRC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival (EFS)</measure>
    <time_frame>Measured up to 2 years after the last participant has enrolled into the study.</time_frame>
    <description>EFS is defined as the number of days from the date of first dose to the date of earliest disease progression, death, or start of a new anti-leukemic therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of participants who move on to stem cell transplant</measure>
    <time_frame>Measured up to 2 years after the last participant has enrolled into the study.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Measured up to 5 years after the last participant has enrolled into the study.</time_frame>
    <description>OS is defined as number of days from the date of first dose to the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Measured up to 5 years after the last participant has enrolled into the study.</time_frame>
    <description>PFS is defined as the number of days from the date of first dose to the date of earliest disease progression (determined by the IRC) or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>Measured up to 5 years after the last participant has enrolled into the study.</time_frame>
    <description>TTP is defined as the number of days from the date of first dose to the date of earliest disease progression (determined by the IRC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 50% reduction in absolute lymphocyte count (ALC)</measure>
    <time_frame>Measured up to 2 years after the last participant has enrolled into the study.</time_frame>
    <description>Time to 50% reduction in ALC is defined as the number of days (hours if applicable) from the date of first dose to the date when the ALC has reduced to 50% of the baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Remission (CR) rate</measure>
    <time_frame>Measured up to 2 years after the last participant has enrolled into the study.</time_frame>
    <description>CR rate is defined as the proportion of participants who achieved a CR or CRi per the NCI-WG criteria (determined by the IRC).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Chronic Lymphocytic Leukemia (CLL)</condition>
  <arm_group>
    <arm_group_label>Venetoclax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax will be administered orally starting with 20 mg once daily (QD); dose escalation will proceed weekly in the following progression: 50 mg QD, 100 mg QD, 200 mg QD, 400 mg QD, as tolerated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>tablet</description>
    <arm_group_label>Venetoclax</arm_group_label>
    <other_name>ABT-199</other_name>
    <other_name>GDC-0199</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant must have a diagnosis of relapsed or refractory chronic lymphocytic
             leukemia (CLL) that meets 2008 Modified International Workshop for Chronic Lymphocytic
             Leukemia (IWCLL) NCI-WG Guidelines and the following:

          -  Participant must have an indication for treatment according to the 2008 Modified IWCLL
             National Cancer Institute-Working Group (NCI-WG) Guidelines;

          -  Participant must have measurable disease (B-lymphocytosis greater than 5 Ã— 10^9/L or
             an enlarged lymph node(s) (LDi &gt; 1.5 cm at baseline) or hepatomegaly or splenomegaly
             due to CLL);

          -  Participant must have relapsed or refractory CLL after receiving at least one prior
             line of therapy

          -  Relapsed - must have completed at least 2 cycles of one prior line of therapy;

          -  Refractory - must have progressed after at least 1 cycle of one prior line of therapy;

          -  Participant must have 17p deletion, assessed by a central laboratory

          -  Participant must have an Eastern Cooperative Oncology Group (ECOG) performance score
             of less than or equal to 2.

          -  Participant must have adequate bone marrow function, coagulation profile, renal, and
             hepatic function, per laboratory reference range at Screening

        Exclusion Criteria:

          -  Participant has undergone an allogeneic stem cell transplant.

          -  Participant has developed Richter's transformation confirmed by biopsy.

          -  Participant has prolymphocytic leukemia.

          -  Participant has active and uncontrolled autoimmune cytopenias (for 2 weeks prior to
             screening), including autoimmune hemolytic anemia (AIHA) and idiopathic
             thrombocytopenic purpura (ITP).

          -  Participant has previously received venetoclax.

          -  Participant is known to be positive for Human Immunodeficiency Virus (HIV).

          -  Participant has received a biologic agent for anti-neoplastic intent within 30 days
             prior to the first dose of study drug.

          -  Participant has received any of the following within 14 days or 5 half-lives
             (whichever is shorter) prior to the first dose of study drug, or has not recovered to
             less than Common Toxicity Criteria (CTC) grade 2 clinically significant adverse
             effect(s)/toxicity(s) of the previous therapy:

               -  Any anti-cancer therapy including chemotherapy, or radiotherapy;

               -  Investigational therapy, including targeted small molecule agents.

          -  Participant has known allergy to both xanthine oxidase inhibitors and rasburicase
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Concord Repatriation &amp; Gen Hos /ID# 201261</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St George Hospital /ID# 206484</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre /ID# 201263</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Anhui Provincial Cancer Hospital /ID# 209458</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peking Univ Peoples Hospital /ID# 156575</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fujian Medical Univ Union Hosp /ID# 156579</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital /ID# 160509</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nanfang Hosp Nanfang Med Uni /ID# 156571</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University /ID# 208913</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province People's Hospital /ID# 156577</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1st Aff Hosp Nanchang Univ /ID# 159142</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Hosp of Jilin Univ /ID# 156532</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiaotong /ID# 156572</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West China Hospital /ID# 156537</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Blood disease hosp of Chinese Academy of Med Sciences(Institute of Hematology) /ID# 157762</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>1st Hosp College Med Zhejian /ID# 156578</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College H /ID# 156576</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chengdu Military General Hosp /ID# 159145</name>
      <address>
        <city>Chengdu</city>
        <zip>610083</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Hospital /ID# 156574</name>
      <address>
        <city>Jinan</city>
        <zip>250021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Hebei /ID# 159143</name>
      <address>
        <city>Shijiazhuang</city>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital /ID# 156536</name>
      <address>
        <city>Soochow</city>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University /ID# 156542</name>
      <address>
        <city>Tianjin</city>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tongji Hosp Tongji Med College /ID# 156589</name>
      <address>
        <city>Wuhan</city>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital /ID# 156573</name>
      <address>
        <city>Zhengzhou, Henan</city>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital /ID# 201650</name>
      <address>
        <city>Christchurch</city>
        <state>Canterbury</state>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Shore Hospital /ID# 204637</name>
      <address>
        <city>Auckland</city>
        <zip>0622</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>China Medical University Hosp /ID# 202767</name>
      <address>
        <city>Taichung City</city>
        <state>Taichung</state>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan Univ Hosp /ID# 210733</name>
      <address>
        <city>Taipei City</city>
        <state>Taipei</state>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital /ID# 202768</name>
      <address>
        <city>Changhua County</city>
        <zip>50006</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University /ID# 202765</name>
      <address>
        <city>Kaohsiung</city>
        <zip>80708</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Linkou Chang Gung Memorial Ho /ID# 203636</name>
      <address>
        <city>Taoyuan City</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>China</country>
    <country>New Zealand</country>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://www.rxabbvie.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 15, 2016</study_first_submitted>
  <study_first_submitted_qc>November 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2016</study_first_posted>
  <last_update_submitted>November 12, 2019</last_update_submitted>
  <last_update_submitted_qc>November 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed chronic lymphocytic leukemia (CLL)</keyword>
  <keyword>Refractory chronic lymphocytic leukemia (CLL)</keyword>
  <keyword>17p deletion</keyword>
  <keyword>venetoclax</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Lymphoproliferative Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html.</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

